Atrial Fibrillation News and Research

RSS
Atrial fibrillation (AF) is the most common arrhythmia. An arrhythmia is a problem with the speed or rhythm of the heartbeat. A disorder in the heart’s electrical system causes AF and other types of arrhythmia. AF occurs when rapid, disorganized electrical signals in the heart’s two upper chambers, called the atria, cause them to contract very fast and irregularly (this is called fibrillation). As a result, blood pools in the atria and isn’t pumped completely into the heart’s two lower chambers, called the ventricles. When this happens, the heart’s upper and lower chambers don’t work together as they should. Often, people who have AF may not even feel symptoms. However, even when not noticed, AF can lead to an increased risk of stroke. In many patients, particularly when the rhythm is extremely rapid, AF can cause chest pain, heart attack, or heart failure. AF may occur rarely or every now and then, or it may become a persistent or permanent heart rhythm lasting for years.
Preoperative statin therapy improves results for isolated CABG and AVR operations

Preoperative statin therapy improves results for isolated CABG and AVR operations

Cardiome partners with LifePharma to commercialize BRINAVESS in Cyprus

Cardiome partners with LifePharma to commercialize BRINAVESS in Cyprus

Respicardia reports results from remede System Pilot Study for central sleep apnea treatment

Respicardia reports results from remede System Pilot Study for central sleep apnea treatment

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

UAB cardiovascular physician becomes first surgeon to use IntellaTip MiFi XP catheter in patient

UAB cardiovascular physician becomes first surgeon to use IntellaTip MiFi XP catheter in patient

Multiple risk factors eliminate impact of AF on stroke risk, but more research is needed

Multiple risk factors eliminate impact of AF on stroke risk, but more research is needed

Secondary prevention drugs produce decline in stroke risk after AMI in diabetic patients

Secondary prevention drugs produce decline in stroke risk after AMI in diabetic patients

NPS MedicineWise reiterates safety messages around newer oral anticoagulants

NPS MedicineWise reiterates safety messages around newer oral anticoagulants

DE-MRI before ablation can stage atrial fibrosis and help predict success treatment

DE-MRI before ablation can stage atrial fibrosis and help predict success treatment

Mass screening programme of 75-76 year olds to identify undiagnosed AF

Mass screening programme of 75-76 year olds to identify undiagnosed AF

Research: General practitioners undertreat women with atrial fibrillation

Research: General practitioners undertreat women with atrial fibrillation

Respicardia reports successful implant of remede System for CSA patients

Respicardia reports successful implant of remede System for CSA patients

Personalised management: The only way to close mortality gap for AF patients

Personalised management: The only way to close mortality gap for AF patients

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Early surgery offers long-term survival, lowers risk of heart failure in mitral valve regurgitation patients

Early surgery offers long-term survival, lowers risk of heart failure in mitral valve regurgitation patients

AliveCor Heart Monitor for iPhone can detect heart rhythm problems, prevent strokes

AliveCor Heart Monitor for iPhone can detect heart rhythm problems, prevent strokes

Isis Pharmaceuticals announces results of ISIS-CRPRx Phase 2 study in RA patients

Isis Pharmaceuticals announces results of ISIS-CRPRx Phase 2 study in RA patients

NPS MedicineWise programs improve prescribing, cardiovascular management in primary care

NPS MedicineWise programs improve prescribing, cardiovascular management in primary care

Clot-inhibiting drug apixaban shows added benefits in adults with non-valvular atrial fibrillation

Clot-inhibiting drug apixaban shows added benefits in adults with non-valvular atrial fibrillation

August edition of NPS RADAR includes reviews for new medicines listed on PBS

August edition of NPS RADAR includes reviews for new medicines listed on PBS

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.